Powder: -20°C for 3 years | In solvent: -80°C for 1 year
SB-3CT 是一种可透过血脑屏障的、竞争性的金属蛋白酶MMP-2和MMP-9抑制剂,Ki 分别为 13.9 nM、600 nM。他对明胶酶具有高选择性。它具有神经保护和抗癌作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 328 | 现货 | ||
2 mg | ¥ 473 | 现货 | ||
5 mg | ¥ 827 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,260 | 现货 | ||
50 mg | ¥ 3,730 | 现货 | ||
100 mg | ¥ 5,330 | 现货 | ||
500 mg | ¥ 10,800 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 852 | 现货 |
产品描述 | SB-3CT is a potent and specific gelatinase inhibitor for MMP-2(Ki=13.9 nM) and MMP-9(Ki=600 nM). |
靶点活性 | MMP2:13.9 nM(Ki), MMP9:600 nM(Ki) |
体外活性 | 在栓子引起的永久性脑缺血小鼠模型中,SB-3CT通过阻碍神经元层粘连蛋白的退化,保护神经元免受缺血性细胞死亡的损害.在L-CI.5sT细胞淋巴小鼠模型中,每天腹腔注射 SB-3CT(5-50 mg/kg),能够抑制肝癌细胞转移.在人前列腺癌细胞骨转移模型中,每天腹腔注射SB-3CT(50 mg/kg ),抑制细胞的生长,骨质溶解以及血管生成. |
体内活性 | SB-3CT能够降低溶骨性反应,有助于骨完整性的保持。在PC3肿瘤细胞中,SB-3CT抑制细胞的生长。在基底膜基质中,SB-3CT直接抑制骨髓内皮细胞浸润和小管形成。 |
激酶实验 | kinase assays: PI3K inhibition by LY294002 is determined in a radiometric assay using purified, recombinant enzymes with 1?μM ATP. The kinase reaction is carried out for 1?hour at room temperature (24oC) and is terminated by addition of PBS. IC50 values are subsequently determined using a sigmoidal dose–response curve fit (variable slope). CK2 and GSK3β (glycogen synthase kinase 3β) inhibition is established by kinase selectivity screening. LY294002 is tested against the Upstate panel of kinases in 10?μM ATP. |
细胞实验 | SB-3CT is dissolved in DMSO (10 mM) and stored (-22°C), and then diluted with appropriate media (DMSO 1%) before use[2]. PC3 cells are seeded in 35-mm dishes (5×104 cells/dish) in complete culture medium. The next day, the medium is replaced with complete medium supplemented with 1% DMSO alone (vehicle) or SB-3CT (final concentrations 0.1-50 μM) in 1% DMSO. At various times, the cells are harvested with trypsin and counted[2]. |
分子量 | 306.4 |
分子式 | C15H14O3S2 |
CAS No. | 292605-14-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Ethanol: 6.1 mg/mL (20 mM)
DMSO: 30.6 mg/mL (100 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
Ethanol / DMSO | 1 mM | 3.2637 mL | 16.3185 mL | 32.6371 mL | 81.5927 mL |
5 mM | 0.6527 mL | 3.2637 mL | 6.5274 mL | 16.3185 mL | |
10 mM | 0.3264 mL | 1.6319 mL | 3.2637 mL | 8.1593 mL | |
20 mM | 0.1632 mL | 0.8159 mL | 1.6319 mL | 4.0796 mL | |
DMSO | 50 mM | 0.0653 mL | 0.3264 mL | 0.6527 mL | 1.6319 mL |
100 mM | 0.0326 mL | 0.1632 mL | 0.3264 mL | 0.8159 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
SB-3CT 292605-14-2 Proteases/Proteasome MMP MMP-2 metalloproteinase gelatinases neuroprotective barrier MMP-9 Matrix metalloproteinases inhibit matrix permeability blood-brain SB 3CT SB3CT anticancer effects Inhibitor inhibitor